Soligenix Inc (SNGX) FinancialsSNGXSoligenix Inc

Soligenix Inc (SNGX) generates its revenue primarily from Specialized BioTherapeutics, which accounts for 100.0% of total sales, equivalent to $2.34K. Understanding this concentration is critical for investors evaluating how SNGX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Soligenix Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -241.65%, provide a clear picture of how effectively SNGX converts its operational activities into shareholder value.

In the context of the broader market, SNGX competes directly with industry leaders such as APRE and UPC. With a market capitalization of $7.30M, it holds a significant position in the sector. When comparing efficiency, SNGX's gross margin of N/A stands against APRE's N/A and UPC's 36.99%. Such benchmarking helps identify whether Soligenix Inc is trading at a premium or discount relative to its financial performance.

Soligenix has reported negative net income for several quarters, with the latest quarter showing a loss of approximately $2.82 million. The current ratio of 2.77 indicates adequate short-term liquidity, but the company has a history of negative net margins, which raises concerns about profitability.